Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company ...

Merck & Co Inc (NYSE:MRK) is making significant progress in its pipeline, with 20 potential new growth drivers, many with blockbuster potential. The Animal Health business delivered strong ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...